LAWSUITS NEWS & LEGAL INFORMATION
FDA Reviews Saxagliptin (Onglyza and Kombiglyze XR) For Heart Failure Risk
Were you looking for Saxagliptin - Onglyza and Kombiglyze XR Side Effects lawsuits?
Washington, DC: The Food and Drug Administration (FDA) has requested clinical trial data from the manufacturer of saxagliptin to investigate a possible association between use of the type 2 diabetes drug and heart failure.
The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.
The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to the FDA by early March 2014, after which the FDA will conduct a thorough analysis and report findings publicly.
At this time, the FDA considers information from the NEJM study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of, all type 2 diabetes drug therapies and cardiovascular risk.
Saxagliptin is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It works by increasing the amount of insulin produced by the body after meals, when blood sugar is high.
Last updated on
The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.
The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to the FDA by early March 2014, after which the FDA will conduct a thorough analysis and report findings publicly.
At this time, the FDA considers information from the NEJM study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of, all type 2 diabetes drug therapies and cardiovascular risk.
Saxagliptin is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It works by increasing the amount of insulin produced by the body after meals, when blood sugar is high.
Legal Help
If you or a loved one has suffered similar damages or injuries, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.Last updated on
DIABETES MEDICATION SIDE EFFECTS LEGAL ARTICLES AND INTERVIEWS
Ozempic and Wegovy Linked to Aspiration Pneumonia
Ozempic Babies, Another Side Effect
Ozempic MDL and Semaglutide Update
May 15, 2024
Patients who have undergone surgeries and endoscopies and taking weight-loss Ozempic, Wegovy and other GLP-1 medications risk aspiration pneumonia. A study conducted by researchers in California found that patients who underwent the procedure were 33 percent more likely to suffer the complication, which can be life-threatening. READ MORE
Ozempic Babies, Another Side Effect
April 17, 2024
Women on birth control or presumed to be infertile have been reporting surprise pregnancies while on Ozempic and similar medications. Referred to as “Ozempic Babies”, they add to increasing concern over the side effects of these diabetes and weight-loss drugs. Healthcare professionals, seeing an association between these medications and unexpected pregnancy on birth control, are warning that these drugs may decrease the effectiveness of oral contraception. READ MORE
Ozempic MDL and Semaglutide Update
March 15, 2024
Fifty-five Ozempic and similar weight loss drug lawsuits have been centralized in Eastern Pennsylvania, with U.S. District Judge Gene E.K. Pratter at the helm of the MDL and scheduled to commence March 14 at the first status conference. The litigation claims that Novo Nordisk's Ozempic, Wegovy and Rybelsus and Eli Lilly's Mounjaro and Trulicity cause gastroparesis and other serious gastrointestinal injuries, and the companies failed to warn patients about the risks associated with GLP-1 receptor agonist medications. READ MORE
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News